Literature DB >> 22310493

Comparison of self- and clinician's ratings of Personal and Social Performance in patients with schizophrenia: the role of insight.

Daniela Schaub1, Martin Brüne, Hans-Werner Bierhoff, Georg Juckel.   

Abstract

BACKGROUND: Patients with schizophrenia are often markedly impaired in their social functioning, partly independent of symptom severity. Few studies have examined patients' self-reporting of their social functioning, how a patient's self-perspective differs from third-party ratings, and whether or not the patients' self-rating of social functioning is influenced by their awareness of illness. SAMPLING AND METHODS: Based on the Personal and Social Performance (PSP) scale as a clinician-administered scale, a PSP self-rating scale for patients was developed. The study included 42 inpatients with schizophrenia. Instruments were the PSP scale, the PSP self-rating scale, the Clinical Global Impression-Severity Scale, and the Scale to Assess Unawareness of Mental Disorder.
RESULTS: A significant correlation was found between PSP self- and clinician's rating for 'socially useful activities', whereas the other PSP subdimensions as well as the total score were not significantly correlated. For patients with high insight, a significantly positive association emerged with 'disturbing and aggressive behaviour', while there was no significant correlation between PSP self- and clinician's ratings for the patients with poor insight into their disorder.
CONCLUSIONS: Patients and clinicians only marginally converge on their judgments concerning the patients' psychosocial functioning. Patients' insight may have a moderating role on the approximation of agreement between self- and third-party ratings. Results are discussed in line with the present literature regarding the accuracy of self-awareness in schizophrenia.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22310493     DOI: 10.1159/000330260

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  6 in total

1.  Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).

Authors:  Leslie Citrome; Anissa Abi-Dargham; Robert M Bilder; Ruth A Duffy; Boadie W Dunlop; Philip D Harvey; Diego A Pizzagalli; Carol A Tamminga; Roger S McIntyre; John M Kane
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

2.  Development of a clinician-administered National Institutes of Health-Brief Fatigue Inventory: A measure of fatigue in the context of depressive disorders.

Authors:  Leorey N Saligan; David A Luckenbaugh; Elizabeth E Slonena; Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  J Psychiatr Res       Date:  2015-06-24       Impact factor: 4.791

Review 3.  Systematic review reveals heterogeneity in the use of the Scale to Assess Unawareness of Mental Disorder (SUMD).

Authors:  Rémy Dumas; Karine Baumstarck; Pierre Michel; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

4.  Towards a framework for treatment effectiveness in schizophrenia.

Authors:  Georg Juckel; Andrea de Bartolomeis; Philip Gorwood; Sergey Mosolov; Luca Pani; Alessandro Rossi; Julio Sanjuan
Journal:  Neuropsychiatr Dis Treat       Date:  2014-09-24       Impact factor: 2.570

5.  The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2020-02-22       Impact factor: 3.630

6.  Multidimensional Evaluation of Awareness in Prader-Willi Syndrome.

Authors:  Jesús Cobo; Ramón Coronas; Esther Pousa; Joan-Carles Oliva; Olga Giménez-Palop; Susanna Esteba-Castillo; Ramon Novell; Diego J Palao; Assumpta Caixàs
Journal:  J Clin Med       Date:  2021-05-07       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.